RT Journal Article
SR Electronic
T1 Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a sixteen-week interval between doses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.17.21263532
DO 10.1101/2021.09.17.21263532
A1 Alexandra Tauzin
A1 Shang Yu Gong
A1 Guillaume Beaudoin-Bussières
A1 Dani Vézina
A1 Romain Gasser
A1 Lauriane Nault
A1 Lorie Marchitto
A1 Mehdi Benlarbi
A1 Debashree Chatterjee
A1 Manon Nayrac
A1 Annemarie Laumaea
A1 Jérémie Prévost
A1 Marianne Boutin
A1 Gérémy Sannier
A1 Alexandre Nicolas
A1 Catherine Bourassa
A1 Gabrielle Gendron-Lepage
A1 Halima Medjahed
A1 Guillaume Goyette
A1 Yuxia Bo
A1 Josée Perreault
A1 Laurie Gokool
A1 Chantal Morrisseau
A1 Pascale Arlotto
A1 Renée Bazin
A1 Mathieu Dubé
A1 Gaston De Serres
A1 Nicholas Brousseau
A1 Jonathan Richard
A1 Roberta Rovito
A1 Marceline Côté
A1 Cécile Tremblay
A1 Giulia C. Marchetti
A1 Ralf Duerr
A1 Valérie Martel-Laferrière
A1 Daniel E. Kaufmann
A1 Andrés Finzi
YR 2021
UL http://medrxiv.org/content/early/2021/09/21/2021.09.17.21263532.abstract
AB While the standard regimen of the BNT162b2 mRNA vaccine includes two doses administered three weeks apart, some public health authorities decided to space them, raising concerns about vaccine efficacy. Here, we analyzed longitudinal humoral responses including antibody binding, Fc-mediated effector functions and neutralizing activity against the D614G strain but also variants of concern and SARS-CoV-1 in a cohort of SARS-CoV-2 naïve and previously infected individuals, with an interval of sixteen weeks between the two doses. While the administration of a second dose to previously infected individuals did not significantly improve humoral responses, we observed a significant increase of humoral responses in naïve individuals after the 16-weeks delayed second shot, achieving similar levels as in previously infected individuals. Our results highlight strong vaccine-elicited humoral responses with an extended interval BNT162b2 vaccination for naïve individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by le Ministere de l Economie et de l Innovation du Quebec, Programme de soutien aux organismes de recherche et d innovation to A.F. and by the Fondation du CHUM. This work was also supported by a CIHR foundation grant #352417, by a CIHR operating Pandemic and Health Emergencies Research grant #177958, a CIHR stream 1 and 2 for SARS-CoV-2 Variant Research to A.F., and by an Exceptional Fund COVID-19 from the Canada Foundation for Innovation (CFI) #41027 to A.F. and D.E.K. Work on variants presented was also supported by the Sentinelle COVID Quebec network led by the LSPQ in collaboration with Fonds de Recherche du Quebec Sante (FRQS) to A.F. This work was also partially supported by a CIHR COVID-19 rapid response grant (OV3 170632) and CIHR stream 1 SARS-CoV-2 Variant Research to MC. A.F. is the recipient of Canada Research Chair on Retroviral Entry no. RCHS0235 950-232424. MC is a Tier II Canada Research Chair in Molecular Virology and Antiviral Therapeutics. V.M.L. is supported by a FRQS Junior 1 salary award. D.E.K. is a FRQS Merit Research Scholar. G.B.B. is the recipient of a FRQS PhD fellowship and J.P. is the recipient of a CIHR PhD fellowship. G.S. is supported by a scholarship from the Department of Microbiologie, Infectiologie et Immunology of Universite de Montreal. R.G. and A.L. were supported by MITACS Acceleration postdoctoral fellowships. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We declare no competing interests.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All work was conducted in accordance with the Declaration of Helsinki in terms of informed consent and approval by an appropriate institutional board. Blood samples were obtained from donors who consented to participate in this research project at Centre Hospitalier de l Universite de Montreal (CHUM) and at Azienda Socio-Sanitaria Territoriale (ASST) Santi Paolo e Carlo, Milan. The study was approved by the respective Institutional Review Boards (no. 19.381 at CHUM and no. 2020/ST/049 at ASST Santi Paolo et Carlo).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis article includes all datasets generated and analyzed for this study. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Author (andres.finzi@umontreal.ca).